Kornimate/medical-research-clean huggingface dataset:
egyptian doctors stresses, knowledge and attitude during covid-19 pandemic

Conditions: Covid-19

Summary: doctors are at high risk of corona virus infection (covid-19) during pandemic. the investigators are aiming to explore the emotions, perceived stressors, knowledge and coping strategies of doctors who are working during covid-19 pandemic in different specialties and in different hospitals by a self assessment questionnaire that was designed and modified from two previously published articles (mentioned in the references), including 7 sections with 88 questions.

background corona virus disease 2019 (covid-19), an infectious respiratory disease caused by a newly discovered corona virus in december 2019, has been recognized as a serious threat to global health. since the who declared covid-19 a pandemic in early march 2020, the who and the center for disease control and prevention (cdc) have been considered the most reliable sources of information for the covid-19 global pandemic. the cdc listed moderate to severe asthma, especially if not well controlled, as high-risk for severe illness from covid-19. a large number of cases occurred among health care workers (hcw), which were contracted within the health care facilities. some of the hcws even died from the covid-19 disease. moreover, it was reported that unrecognized, asymptomatic patients transferred to their family or close contacts. all these factors were alarming and potentially distressing for the hospital staff who worked during the pandemic. the severe acute respiratory syndrome (sars) epidemic in 2003 also involved disease transmission to hcws. even though the fatality rates for sars were lower than for covid-19 infection, nonetheless, they were a cause of significant stress, emotional turmoil, and concern for all the sars healthcare providers. the emotions, perceived stressors, complete knowledge assessment and coping strategies of hcws especially doctors during covid-19 have not been explored. these issues were the intended focus of the study.

Eligibility criteria:
inclusion criteria: * doctors from different specialties exclusion criteria: * doctors who stopped working in the pandemic

Keywords: stresses covid-19 doctors
sirolimus & mycophenolate mofetil as gvhd prophylaxis in myeloablative, matched related donor hct

Conditions: Leukemia; Lymphoma, Non-Hodgkin; Hematologic Diseases; Acute GVHD

Summary: gvhd prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, mds, high risk nhl and hl

to explore the novel combination of sirolimus and mycophenolate mofetil (mmf) as graft versus host disease (gvhd) prevention in hla matched related donor blood or marrow transplantation (bmt). this study will report the toxicities associated with this drug combination and also explore possible correlations between specific blood cell types and antibody production during this therapy.

Eligibility criteria:
inclusion criteria: * disease categories: (one of the following) * aml, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease * aml, age 51-60 years of age, in first or subsequent remission or relapsed/refractory disease * aml with multilineage dysplasia * all, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease * all, age 51 - 60 years in first or subsequent remission or relapsed/refractory disease * cml beyond 2nd chronic phase or in blast crisis * mds; includes world health organization classifications of refractory anemia with excess blasts-1 (raeb-1), raeb-2 and therapy-related mds * myeloproliferative disorders; mds with poor long-term survival including myeloid metaplasia and myelofibrosis * high risk nhl in first remission * relapsed or refractory nhl * hl beyond first remission * males and females of any ethnic background 2 - 60 years of age * karnofsky performance status ≥ 70% or lansky performance status \> 70% for patients \< 16 years of age. * matched related donor identified: 6/6 hla-a, b and drb1 * willingness to take oral medications during the transplantation period * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * prior myeloablative allogeneic or autologous hct * hiv infection * pregnant * lactating females * evidence of uncontrolled active infection * organ dysfunction: * serum creatinine \> 1.5 mg/dl or 24 hour creatinine clearance \< 50 ml/min * direct bilirubin, alt or ast \> 2 x uln * in adults dlco \< 60% predicted and in children room air oxygen saturation \< 92% * in adults, left ventricular ejection fraction \< 45% and in children, shortening fraction \< 26% * fasting cholesterol \> 300 mg/dl or triglycerides \> 300 mg/dl while on lipid-lowering agents. * patients receiving investigational drugs unless cleared by the pi. * patients with prior malignancies except basal cell carcinoma or treated carcinoma in-situ. * cancer treated with curative intent \> 5 years will be allowed. * cancer treated with curative intent ≤ 5 years will not be allowed with pi approval.
efficiency of inspiratory muscle training in elderly people

Conditions: Healthy

Summary: efficiency of inspiratory muscle training in elderly people. outcomes are lung function, muscle strength and chest expansion.


Eligibility criteria:
inclusion criteria: * healthy exclusion criteria: * pulmonary diseases * cognitive disorders
brown fat activity and white fat accumulation

Conditions: Hodgkins Lymphoma; Non-hodgkins Lymphoma

Summary: white and brown adipocytes differ in their expression of hormones, cytokines, and inflammatory factors, and they modulate different biological functions. while white adipose tissue (wat) serves as the primary site of energy storage, brown adipose tissue (bat) instead metabolizes fat to produce heat and regulate body temperature. bat is likely present in all humans, but the low prevalence of bat depiction in adults and elderly subjects has hindered longitudinal assessments of the relation between bat activity and wat. under typical imaging conditions, bat is detected more frequently in children and teenagers than in adults with malignancy. since most children with cancer have significantly shorter treatment courses and greater survival rates compared to adult patients, the investigators have the ability to examine the relation of repeated measures of body composition and bat by selecting pediatric patients. in this study, the investigators will longitudinally examine whether bat activity is related to changes in weight and the amounts of sat, vat, and abdominal muscle in children successfully treated for pediatric cancer.


Eligibility criteria:
inclusion criteria: * patients had pet/ct scans with evidence of malignant disease * patients had no metabolically active bat at diagnosis on their pet/ct scan * patients were disease free within 1 year of diagnosis exclusion criteria: * patients had pet/ct scans with no evidence of malignant disease * patients with metabolically active bat at diagnosis on their pet/ct scan * patients were not disease free within 1 year of diagnosis

Keywords: brown adipose tissue
safety and tolerability of hsc835 in patients with hematological malignancies

Conditions: Acute Myelocytic Leukemia; Acute Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia; Marginal Zone Lymphoma; Follicular Lymphomas; Large-cell Lymphoma; Lymphoblastic Lymphoma; Burkitt's Lymphoma; High Grade Lymphomas; Mantle-cell Lymphoma; Lymphoplasmacytic Lymphoma

Summary: this study evaluated the safety and tolerability of using hsc835 in patients with hematological malignancies.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis that qualifies them for a ducbt * absence of recent active mold infection * adequate organ function * availability of eligible donor material exclusion criteria: * pregnancy or breastfeeding women and women of child-bearing potential unless two acceptable forms of contraception are being used * human immunodeficiency virus (hiv) infection * active infection * extensive prior chemotherapy * prior myeloablative allotransplantation or autologous transplant.

Keywords: hematologic malignancies leukemia lymphoma
brexpiprazole for the treatment of patients with agitation associated with dementia of the alzheimer's type

Conditions: Agitation Associated With Dementia of the Alzheimer's Type

Summary: to evaluate the superiority of brexpiprazole 1 mg or 2 mg over placebo after a 10-week treatment regimen for agitation associated with dementia of the alzheimer's type in patients who require medication, and to investigate the safety of brexpiprazole and identify the optimum dose.


Eligibility criteria:
inclusion criteria: * patients who satisfy both of the following diagnostic criteria: 1. diagnosis of "dementia due to alzheimer's disease" according to dsm-5. 2. diagnosis of "probable alzheimer's disease" according to nincds-adrda. * hospitalized patients or care facility patients or care at home patients * patients with an mmse score of 1 to 22 * patients who have the agitation defined according to the "consensus provisional definition of agitation in cognitive disorders" from the international psychogeriatric association (ipa) exclusion criteria: * patients who have dementia other than dementia of the alzheimer's type * patients diagnosed with delirium between 30 days before the screening examination and baseline evaluation according to dsm-5. * patients diagnosed with any of the following disorders according to dsm-5: * schizophrenia spectrum and other psychotic disorders * bipolar and related disorders * major depressive disorder
a clinical study comparing the inflammatory response of the ex-press mini shunt to trabeculectomy

Conditions: Glaucoma

Summary: the less invasive nature of the ex-press mini shunt with mitomycin c induces less post-operative inflammation than trabeculectomy with mitomycin c.

the purpose of this study is to quantify the degree of post-operative inflammation in eyes which have undergone either trabeculectomy filtering surgery or ex-press mini shunt insertion. early intraocular pressure control and postoperative complications will also be noted.

Eligibility criteria:
inclusion criteria: all subjects must: 1. be willing and able to provide written informed consent. 2. be able and willing to follow instructions on the use of post- operative medication and likely to complete the entire course of the study. 3. be male or female of any race at least 18 years of age. 4. have medically uncontrolled glaucoma for which they have elected to undergo surgery. 5. diagnosed with primary open angle glaucoma, pigmentary or pseudoexfoliation glaucoma. exclusion criteria: no subject may: 1. have any contraindication to intraocular surgery. 2. diagnosed with: primary angle closure glaucoma, normal tension glaucoma, secondary glaucoma, neovascular glaucoma. 3. have any active ocular disease other than glaucoma that would interfere with study parameters (such as: uveitis, ocular infection, or severe dry eye). subjects with mild chronic blepharitis, age-related macular degeneration and background diabetic retinopathy may be enrolled at the discretion of the investigator. 4. have laser alt or slt within the past 3 months or cataract surgery within the last six months. 5. require use of ocular nsaid or systemic steroids. 6. have known allergy or sensitivity to mitomycin c 7. have corneal abnormalities that would interfere with the ability to obtain an adequate laser flare measurement. 8. be concurrently enrolled in an investigational drug or device study or participation within the last 30 days in any investigational drug or device study. 9. be pregnant, nursing, planning a pregnancy, or be of childbearing potential and not using a reliable form of contraception (a woman is considered of childbearing potential unless she is postmenopausal, has had a uterus and/or both ovaries removed, or has had a bilateral tubal ligation). 10. have a situation or condition that in the investigator's opinion may put the subject at significant risk, may confound the study results, or may interfere significantly with participation in the study.

Keywords: inflammatory response
a study on bms-986177 for the prevention of a stroke in patients receiving aspirin and clopidogrel

Conditions: Acute Ischemic Stroke; Transient Ischemic Attack (TIA)

Summary: the purpose of this clinical study is to determine whether the addition of an oral factor xia inhibitor to aspirin and clopidogrel is more effective than standard therapy in secondary stroke prevention.


Eligibility criteria:
inclusion criteria: * male and female ≥40 years of age * acute ischemic stroke or transient ischemic attack * intracranial or extracranial atherosclerotic plaque proximal to the affected brain area exclusion criteria: * predicted inability to swallow study medication * any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding * use of thrombolytic therapy or mechanical thrombectomy for treatment of index stroke other protocol defined inclusion/exclusion criteria could apply
dynamic echocardiographic optimisation response study

Conditions: Heart Failure

Summary: the aim of this study is to evaluate the effects of heart rate optimization and guided a-v and v-v delay from color doppler echocardiography, in subjects affected by heart failure with reduced ejection fraction and crt-d device wearers who did not respond to device implantation in clinical, electrophysiological, and other terms.


Eligibility criteria:
inclusion criteria: 1. patient must be 18 to 85 years of age inclusive, at the time of signing the informed consent form; 2. heart failure with ventricular ejection fraction left \<45%; 3. presence of crt-d devices in a non-responder patient for cardiac resynchronization 4. nyha \>ii; 5. resting heart rate \<65 beats per minute; 6. biventricular pacing \>97%. exclusion criteria: 1. age \ 85 years; 2. insufficient functional capacity to complete the tests required by the research protocol; 3. permanent atrial fibrillation
genetic analysis and multimodal retinal imaging of asymptomatic fovea plana cases in the general population

Conditions: Fovea Plana; Albinism

Summary: albinism is a genetic condition, resulting from mutations in at least 19 known genes responsible for the production of melanin in the skin, hair and eyes. ophthalmological manifestations are a constant feature of this disease. albinism is believed to be responsible for 5% of visual impairments worldwide and all albino patients have some degree of fovea plana. in the milder forms, it is a slightly less marked foveolar depression with conservation of the normal diameter of the cones and, therefore, good visual function. in addition to its known association with various ocular pathologies such as albinism, aniridia, nanophthalmia and retinopathy of prematurity, fovea plana was found in 3% of a population of normal children (without known ocular or systemic pathology) in a study conducted in 2014 to determine a pediatric normative basis for macular volume measured by optical coherence imaging (stratus oct). more recently, a study carried out at the hospital foundation adolphe de rothschild showed that at least 35% of parents of albino children, who are totally asymptomatic, present with fovea plana in oct. this frequency is higher than the 3% prevalence of fovea plana in asymptomatic subjects without a family history of albinism, suggesting a modulation of heterozygosity for a known gene for albinism. the aim of this study is to verify, in patients with fortuitously discovered fovea plana (preoperative oct for cataract surgery), with conservation of visual function and without known or manifest albinism, whether they are carriers of mutation in one of the genes referenced for albinism. this will also allow us to characterize these foveolar profiles in oct according to the classification of thomas et al., as well as in terms of retinal capillary density in oct-angiography, in order to know whether it is the same type of fovea plana or if the phenotype differs depending on the genetic damage.


Eligibility criteria:
inclusion criteria: * patient over 18 years old; * diagnosis of fovea plana in one or both eyes, confirmed by two ophthalmologists blinded to each other from oct-b imaging; exclusion criteria: * known albinism * known family history of albinism * history of eye surgery other than cataract * alteration of macular visual function (loss of visual acuity independent of a disorder of the environments, central scotoma, metamorphopsies, etc.) * presence of another anomaly in oct in addition to the fovea plana (epiretinal membrane, damage to the external retina, etc.) * syndromic fovea plana * pregnant or breastfeeding woman

Keywords: carriers general population
study to evaluate effect of intranasal teriparatide on bone mineral density in postmenopausal women with low bmd

Conditions: Osteopenia; Osteoporosis

Summary: this study is being conducted to compare the effect of increasing nasal teriparatide dosing on percent change in bone mineral density (bmd) of the lumbar spine after 24 weeks of therapy in postmenopausal women with low bone mineral density.


Eligibility criteria:
inclusion criteria: * postmenopausal female patients up to 89 years, inclusive; * bmi ≤ 35 kg/m2, inclusive; * in good health, determined by medical history and physical examination, as well as normal 12-lead ecg and vital signs; * females will be non-pregnant, non-lactating, and either post-menopausal for at least 1 year, surgically sterile (including tubal ligation, hysterectomy) for at least 3 months, until 30 days following study completion be willing to use an approved method of contraception; * have a minimum of two evaluable non-fractured lumbar vertebrae. * have low bone mineral density defined as having a t-score ≤ -2.0 as determined by dxa scan at either the lumbar spine (l1-l4) or total hip exclusion criteria: * serious medical condition * history of diseases which affect bone metabolism other than postmenopausal osteoporosis such as paget's disease, any secondary causes of osteoporosis, hypoparathyroidism, or hyperparathyroidism * have a history of cancer within the past 5 years, except for basal cell carcinoma * have hypocalcemia or hypercalcemia from any cause or have a recent history of kidney stones or pre-existing hypercalciuria; * have used any of the mostly commonly prescribed osteoporosis medications within 3 months of starting the investigational product, or for more than 1 month at any time within 6 months prior to starting investigational product.

Keywords: osteoporosis osteopenia bone mineral density teriparatide
recurrent bacterial vaginosis and vaginal acidifying gel trial

Conditions: Bacterial Vaginosis

Summary: bacterial vaginosis (bv) is a common, complex clinical syndrome characterized by alterations in the normal vaginal flora. bacterial vaginosis has been associated with a variety of adverse health outcomes including endometritis; post-abortion endometritis; nongonococcal, nonchlamydial pelvic inflammatory disease; and an increased risk of acquiring and transmitting hiv infection. in pregnancy, bv is associated with premature rupture of the membranes, chorioamnionitis, amniotic fluid infection, preterm labor, preterm birth, and postpartum endometritis. several studies have documented increased postpartum complications in the newborn and infants. the etiology of bv is poorly understood but recurrence is quite common despite treatment. documented recurrence rate of up to 30% within three months are reported. small studies have shown that adding vaginal acidifying gel to standard antibiotic regimens may reduce recurrence rates of bv. we plan an rct comparing standard antibiotic therapy to antibiotics plus vaginal acidifying gel. our hypothesis is that the addition of an acidifying gel will decrease the chance of recurrence of bv within 3 months.

women with recurrent bv will be randomly assigned to standard care of metronidazole vs metronidazole plus vaginal acidifying gel. symptoms and presence of bv will be measured at followup.

Eligibility criteria:
inclusion criteria: 1. all women of between 18-50 years of age. 2. confirmed current diagnosis of bv using amsel's criteria. 3. women with at least total 2 confirmed episodes of bv including most recent episode (by amsel's criteria) within a six month period or at least total three or more in the past twelve months exclusion criteria: 1. patient who received antibiotic therapy within the past two weeks. 2. patients who had co-existing gonorrhea or chlamydia infection 3. any contraindications or sensitivity to taking the vaginal gel. 4. allergy to metronidazole 5. alcoholics or those unable to abstain from alcohol consumption. 6. pregnancy

Keywords: bacterial vaginosis vaginal acidifying gel recurrence
kt® in patients with cervical spine surgery

Conditions: Pain; Cervical Spinal Stenosis; Disc, Herniated; Cervical Spondylosis

Summary: aim of the study was to investigate the effect of kinesio taping application on upper trapezius muscle after cervical spine surgery.

patients will be randomly divided into three groups. the first group will receive conservative treatment and kinesio taping application. the second group will receive conservative treatment and the third group will receive only kinesio taping application. the treatment procedure will continue for post-operatively three days and assessments will be done four times; before the surgery, post-operative 1st day, postoperative 3rd day and two weeks after surgery. data will be recorded on patient assessment file and transferred to the computer. data analysis will be performed with spss.22.

Eligibility criteria:
inclusion criteria: * to be voluntary participation in the study, * aged 25-75 years old, * to be diagnosed with cervical disc herniation, cervical stenosis and cervical spondylolisthesis * no mental problem, sensory or motor aphasia in order to understand and answer the evaluation questions correctly. exclusion criteria: * history of surgery, * allergic reaction to kinesio taping, * primary or metastatic neoplasm in cervical spine, * history of different treatment for neck pain during the study period, * individuals with any congenital deformity in the spine, * having any rheumatologic, neurological and orthopedic disease.

Keywords: kinesio tape pain functionality cervical spine surgery